

# Key Information Document



## Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

## Product

**Name of Product:** Pacific North of South EM All Cap Equity GBP I Distributing

**PRIP Manufacturer:** Pacific Capital Partners Limited

**ISIN:** IE00BFZ4H223

**Website:** [www.pacificam.co.uk](http://www.pacificam.co.uk)

Call +44 (0)20 3970 3100 for more information.

The Central Bank of Ireland (CBI) is responsible for supervising Pacific Capital Partners Limited in relation to this Key Information Document.

The Product is a sub-fund of Pacific Capital UCITS Funds plc (the Company) which is authorised in Ireland and regulated by the Central Bank of Ireland and has been registered for sale in other EEA Member States.

Pacific Capital Partners Limited is authorised in England and regulated by the Financial Conduct Authority (FCA).

**This Key Information Document is accurate as at 01 January 2023.**

## What is this product?

### Type

UCITS

### Term

The Company is an open-ended Product with no specified maturity date.

### Objectives

The investment objective of the Product is to achieve long-term capital appreciation. The Product is considered to be actively managed, which means that the Sub-Investment Manager is not constrained by any index or benchmark in the selection of investments. The performance of this Product is measured against the MSCI Emerging Markets Gross Total Return Index (in the currency of the Class) for the purposes of the calculation of performance fees for the Class. The Product does not intend to track this index. This index was chosen because it represents the minimum level of return that is expected from the Product over the stated time period. The majority of the Product will not be components of the index. The Product seeks to achieve this objective through investing primarily in equity and equity related securities (such as warrants and rights issues) of companies listed on or dealt in Recognised Markets in emerging markets or which are listed on or dealt in Recognised Markets outside of the emerging markets but which generate the bulk of their earnings in emerging markets. The Product will only take long positions for investment purposes. The maximum anticipated long exposure of the Product is 115% of its Net Asset Value (100% direct investment and 15% leveraged exposure). The Product may take short exposures for hedging purposes only and the maximum anticipated exposure in this regard is 20% of its Net Asset Value. The Base Currency of the Product is US Dollar. Non Base Currency Share Classes are unhedged. No more than 20% of the Net Asset Value of the Product may be invested in the Russian market. The investment team combines top-down analysis and

bottom up company research in order to build a portfolio of liquid and diversified holdings. The Product's investments will have no industrial or sectoral focus. The Product may use derivatives for investment purposes and / or efficient portfolio management purposes. Further information in respect of the Product's use of derivatives is set out in the Derivatives section of the Product's Supplement. The Product may enter in to Repurchase Agreements and Reverse Repurchase Agreements, and Stocklending Agreements for the purpose of efficient portfolio management.

### Intended Retail Investor

This product is intended for investors who understand the degree of risk, who can tolerate a medium to high level of volatility and who are able to bear any losses (which may equal the whole amount invested) that may result from an investment in the Product. The Product is designed to form part of a portfolio of investments.

### Important Information

- The Company is an investment company with variable capital incorporated in Ireland with registered number 553111 and established as an umbrella fund with segregated liability between sub-funds.
- The Company's Depository is Citi Depository Services Ireland Designated Activity Company.
- Further information about the Company, the Product and the different classes of shares (including a copy of the current Prospectus, the Supplement and most recent Report and Financial Statements) are available online at [www.pacificam.co.uk](http://www.pacificam.co.uk).
- Investors may switch shares in the Product for shares in other sub-funds of Pacific Capital UCITS Funds plc provided that they satisfy the criteria applicable to investments in the other sub-fund(s). Further information on switching is contained in the Prospectus and the Supplement.

## What are the risks and what could I get in return?

### Risk Indicator



The risk indicator assumes that you keep the product for 5 years. The actual risk can vary significantly if you cash in at an early stage and you may get back less.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

This rates the potential losses from future performance at a medium level, and poor market conditions could impact the capacity of the PRIIPs manufacturer to pay you.

We have classified this product as 4 out of 7, which is a medium risk class.

Due to effects of unusual market conditions, other risks could be triggered, refer to "Risk Considerations" in the Prospectus and Supplement.

This product does not include any protection from future market performance so you could lose some or all of your investment.

If we are not able to pay you what is owed, you could lose your entire investment.

## Performance Scenarios

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product and a suitable benchmark over the last 10 years. Markets could develop very differently in the future.

The stress scenario shows what you might get back in extreme market circumstances.

The unfavourable scenario occurred for an investment in the benchmark between June 2021 and October 2022.

The moderate scenario occurred for an investment in the benchmark between September 2016 and September 2021.

The favourable scenario occurred for an investment in the benchmark between January 2016 and January 2021.

Recommended holding period: 5 years.

Example Investment: GBP 10,000.

Scenarios		If you exit after 1 year	If you exit after 5 years
<b>Minimum</b>	<b>There is no minimum guaranteed return. You could lose some or all of your investment.</b>		
Stress	What you might get back after costs	2,860 GBP	2,480 GBP
	Average return each year	-71.45 %	-24.34 %
Unfavourable	What you might get back after costs	7,440 GBP	8,280 GBP
	Average return each year	-25.64 %	-3.71 %
Moderate	What you might get back after costs	10,510 GBP	15,200 GBP
	Average return each year	5.05 %	8.74 %
Favourable	What you might get back after costs	15,910 GBP	22,520 GBP
	Average return each year	59.10 %	17.63 %

## What happens if Pacific Capital Partners Limited is unable to pay out?

You may face a financial loss should the Manufacturer or Depository default on their obligations. There is no compensation or guarantee scheme in place which may offset, all or any of this loss.

## What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

### Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest and how long you hold the product. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year, you would get back the amount that you invested (0 % annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.
- GBP 10,000 is invested.

	If you exit after 1 year	If you exit after 5 years
Total costs	138 GBP	1,078 GBP
Annual cost impact (*)	1.4%	1.5% each year

(\*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 10.2% before costs and 8.7% after costs.

We may share part of the costs with the person selling you the product to cover the services they provide to you. They will inform you of the amount.

### Composition of costs

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	0% of the amount you pay in when entering this investment	0 GBP
Exit costs	We do not charge an exit fee for this Product.	0 GBP
<b>Ongoing costs [taken each year]</b>		
Management fees and other administrative or operating costs	0.9% of the value of your investment per year. This is an estimate based on actual costs over the last year.	91 GBP
Transaction costs	0.5% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	47 GBP
<b>Incidental costs taken under specific conditions</b>		
Performance fees	There is no performance fee for this Product.	0 GBP

## How long should I hold it and can I take money out early?

### Recommended holding period: 5 years

This product should be considered a medium to long term investment. This means at least 5 years or more. You can sell your shares in the product on any Dealing Day as defined in the Prospectus, by using one of the methods described in the Prospectus. No exit fees will be charged. Please refer to the 'Composition of Costs' table for more information.

## How can I complain?

If you have any complaints about the Company, the Product or the conduct of the PRIIP Manufacturer, complaints can be lodged via the following methods:

- 1) E-mail: [compliance@pacificam.co.uk](mailto:compliance@pacificam.co.uk)
- 2) Mail: The Head of Compliance, Pacific Asset Management, 1 Portland Place, London, W1B 1PN, UK

Please also refer to the “Complaints Procedure” section on the PRIIP Manufacturer’s website at [www.pacificam.co.uk](http://www.pacificam.co.uk) for more information.

Complaints regarding the conduct of the person(s) advising on or selling the product should be addressed to the relevant person(s) or to their organisation.

## Other relevant information

- The Company’s Management Company is KBA Consulting Management Limited which is authorised in Ireland and regulated by the Central Bank of Ireland.
- The Product is managed by Pacific Capital Partners Limited (the Investment Manager) which is authorised and regulated by the Financial Conduct Authority.
- The Product is sub-managed by North of South Capital LLP (the Sub-Investment Manager) which is authorised and regulated by the Financial Conduct Authority.
- The Net Asset Value per share, past performance and 10 year performance scenarios for the Product are available at [www.pacificam.co.uk](http://www.pacificam.co.uk).
- The Product is subject to Irish taxation legislation which may have an impact on your personal tax position as an investor in the Product. Investors should consult their own tax advisers before investing in the Product.
- Details of the remuneration policy of the Manager is available at <https://kbassociates.ie> A paper copy of the remuneration policy will be made available free of charge upon request.

The representative and paying agent in Switzerland is BNP PARIBAS, Paris, Zurich branch, Selnaustrasse 16, 8002, Zurich, Switzerland. The Prospectus, the key information documents (KIDs), the memorandum and articles of association as well as the annual and semi-annual reports may be obtained free of charge from the representative in Switzerland.